Emmanuel Ozimba, MD
Family Medicine · Cuthbert, GANPI 1245233832
Payments from drug & device makers
Across 167 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$763
- AbbVie$743
- Bayer$392
- Novo Nordisk$220
- Biohaven Pharmaceutical Holding Company Ltd.$129
- Lilly USA, LLC$125
- plus $642 from 17 others
What the payments were for
- Food & beverage$3,013100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 44 | $763 |
| AbbVie | 53 | $743 |
| Bayer | 16 | $392 |
| Novo Nordisk | 10 | $220 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $129 |
| Lilly USA, LLC | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 6 | $116 |
| Pfizer | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| AstraZeneca | 3 | $58 |
| Neurocrine Biosciences, Inc. | 3 | $50 |
| Novartis | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Boehringer Ingelheim | 2 | $35 |
| Philips North America LLC | 2 | $26 |
| Lundbeck LLC | 1 | $26 |
| Edwards Lifesciences | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$125
How this compares
$3,013 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 608 | $167,010 |
| RexultiBrexpiprazole | 110 | $63,251 |
| NuedextaDextromethorphan Hbr/Quinidine | 71 | $54,863 |
| TrulicityDulaglutide | 56 | $53,255 |
| JanuviaSitagliptin Phosphate | 176 | $45,336 |
| JardianceEmpagliflozin | 148 | $40,635 |
| LinzessLinaclotide | 71 | $40,293 |
| MounjaroTirzepatide | 24 | $34,075 |
| TradjentaLinagliptin | 125 | $29,146 |
| Metformin Er GastricMetformin Hcl | 16 | $27,491 |
| FarxigaDapagliflozin Propanediol | 103 | $27,063 |
| VraylarCariprazine Hcl | 32 | $26,521 |
| Invega SustennaPaliperidone Palmitate | 12 | $25,696 |
| RybelsusSemaglutide | 20 | $25,301 |
| EntrestoSacubitril/Valsartan | 77 | $24,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $72 | $167,010608 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $125 | $87,33080 claims |
| Boehringer IngelheimJardiance, Tradjenta | $35 | $69,780273 claims |
| AbbVieLinzess, Vraylar | $743 | $66,814103 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $116 | $63,251110 claims |
| AstraZenecaFarxiga, Brilinta | $58 | $40,749183 claims |
| Novo NordiskRybelsus, Ozempic | $220 | $37,18232 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $19 | $36,78268 claims |
| GSKTrelegy Ellipta, Arexvy | $763 | $30,42260 claims |
| NovartisEntresto | $37 | $24,05477 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Cuthbert
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.